NCT01063257已完成1 期
A Phase I/II Multicenter Study of IV Clofarabine in Patients With High-Risk Myelodysplastic Syndrome Who Have Failed Therapy With Azacitidine: the NIDEVOL Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 76
- 试验地点
- 5
- 主要终点
- To determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs)
研究概览
简要总结
This study aims to determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs) of low dose IV clofarabine for MDS patients after treatment failure of azacitidine.
详细描述
The study is an open-label, 3+3 dose-escalation, phase I/II study.The duration of enrollment in the phase I study is 12 months.
Fourteen patients will be enrolled at the RD using the selected dosing in each cohort, for an enrollment period of 12 months.
Each patient may receive up to 8 courses, every 4 to 8 weeks in a D1-D5 schedule or every other day from D1 to D10.
Each patient will be followed for up to 24 months.
Primary endpoint of the phase I part:
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients aged 18 years or more with MDS according to FAB classification and intermediate-2 or high IPSS risk scores, or CMML (with WBC < 13 x 109/L and bone marrow blasts > 10 %) according to WHO classification, or AML according to WHO classification if less than 30 % bone marrow blasts (RAEB-T according to FAB MDS classification or AML according to WHO classification with more than 30 % with bone marrow blasts only if preceded by a proven MDS phase.
- •Patients previously treated by azacitidine (Vidaza®) in proven progression, or stable after 6 courses with ongoing transfusion dependent anemia (> 4 RBC units in the 8 weeks preceding inclusion (as erythroid response in IWG 2006 criteria is reduction of at least 4 RBC units in 8 weeks).
- •Previous biological and or targeted therapies of MDS or AML are allowed if stopped more than 1 month before inclusion.
- •ECOG PS ≤
- •Adequate renal and liver function :
- •i.e. Serum creatinine < 110 microM in men or 90 microM in women. If plasma creatinine level < 90 - 110 microM, then the estimated glomerular filtration rate (GFR) must be < 50 mL/min/1.73 m2 as calculated by the Modification of Diet in Renal Disease (MDRD) equation where Predicted GFR (mL/min/1.73 m2) = 32788 x (plasma creatinine level (microM)-1.154 x (age in years)-0.023 x (0.742 if patient is female) x (1.212 if patient is African American)
- •Bilirubin < 1.5 x ULN, (except increased unconjugated bilirubin due to dyserythropoiesis).
- •Aspartate transaminase (AST)/alanine transaminase (ALT) < 2.5 × ULN and Alkaline phosphatase < 2.5 × ULN.
- •Absence of pregnancy or lactation in female patients (Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment).
- •Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
- •Provided signed written informed consent.
- •Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
排除标准
- •Patients with AML and bone marrow blasts count of 20-30%, if candidates to intensive AML type chemotherapy.
- •Known hypersensitivity to clofarabine or excipients.
- •Concomitant malignant disease.
- •Active uncontrolled infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
- •Concomitant severe cardiovascular disease, i.e. congestive heart failure (NYHA grade > 3).
- •Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
- •No affiliation to a national insurance scheme directly or to an equivalent system.
- •Chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
- •Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute toxicities from any previous therapy.
研究组 & 干预措施
Cohort A
Experimental
Clofarabine treatment at D1-D5
干预措施: Clofarabine (Drug)
Cohort B
Experimental
Clofarabine treatment at D1, D3, D5, D8, D10
干预措施: Clofarabine (Drug)
结局指标
主要结局
To determine the maximal tolerated dose (MTD) and dose limiting toxicities (DLTs)
时间窗: 1-2 months
After one course treatment.
次要结局
- To determine response rates.(1-16 months.)
- To evaluate the response duration.(1-16 months)
- To evaluate time to IPSS progression.(1-16 months)
- To evaluate loss of RBC transfusion independence and hospitalization duration.(1-16 months)
- To evaluate rates of rehospitalization for non-hematological toxicities, severe bleeding or febrile neutropenia.(1-16 months)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Safety of Clofarabine With Multiagent Chemotherapy in Childhood Acute Lymphoblastic LeukemiaAcute Lymphoid Leukemia RelapseAcute Lymphoid Leukemia Relapse After Bone Marrow TransplantNCT01279096University Hospital, Lille20
终止
1 期
Phase I Dose-Escalation Trial of Clofarabine Followed by Escalating Doses of Fractionated Cyclophosphamide in Children With Relapsed or Refractory Acute LeukemiasAcute Promyelocytic LeukemiaMyeloproliferative DisordersAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyelodysplastic SyndromeAcute LeukemiaChronic Myelogenous LeukemiaChronic Myelomonocytic LeukemiaMyelofibrosisJuvenile Myelomonocytic LeukemiaNCT00852709Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins35
已完成
1 期
Phase I Trial of Clofarabine in Combo w/ HD Etoposide & Cyclophosphamide and APBSCT for Pts w/ High-Risk or Refractory NHLNon Hodgkin's LymphomaNCT00477945Indiana University School of Medicine18
终止
1 期
A Study of Oral Clofarabine in Adult Patients With Myelodysplastic Syndromes (MDS)Myelodysplastic SyndromesNCT00750334Genzyme, a Sanofi Company2
已完成
1 期
A Phase I Trial of Myeloablative Conditioning w/ Clofarabine and HD Busulfan for Pts w/ Refractory Heme Malignancies Undergoing Allo PBSCTHematologic MalignanciesNCT00477542Indiana University School of Medicine18